Pharmaceuticals News and Research

RSS

Researchers developing probe wire to better understand causes of degenerative brain diseases

Researchers are developing a tiny wire that will speed up the discovery of new drugs and could one day unlock the mysteries of illnesses such as Alzheimer's or Lou Gehrig's disease.

4 Jun 2015

AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform.

3 Jun 2015

KNAUER ‘s Portfolio of LC instruments and columns as well as other high pressure equipment

One of KNAUER´s core competencies is the development of high-pressure dosing pumps. Those pumps have to fulfill very demanding tasks in food, chemical, and pharmaceutical industries...

From KNAUER Wissenschaftliche Geräte GmbH 3 Jun 2015

Hi-Tech Pharmaceuticals signs definitive agreement to acquire FormuTech Nutrition

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition products, Contract Manufacturing, and FormuTech Nutrition, one of the fastest-growing Sports Nutrition companies in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire FormuTech.

3 Jun 2015

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA).

3 Jun 2015

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

Takara Bio Europe AB, formerly Cellartis AB, a wholly-owned subsidiary of Takara Bio Inc., announced today that it is launching an advanced cell culture medium for iPS cell culture. This chemically-defined culture medium is pre-clinical grade, free from human- and animal-derived components, and designed for efficient expansion of undifferentiated human iPS cells.

3 Jun 2015

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it has entered into a termination agreement with AstraZeneca, such that all the rights to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product candidate, tenapanor, are returned to Ardelyx.

3 Jun 2015

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.

3 Jun 2015

Genentech, Seragon, Regeneron and Avalanche receive Allicense 2015 Breakthrough Award for Deals of the Year

The Intellectual Property and Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, recently honored Genentech Partnering and Seragon, and Regeneron and Avalanche with the Allicense 2015 Breakthrough Award for Deals of the Year.

3 Jun 2015

Survey shows most men with advanced prostate cancer ignore their symptoms as disease progresses

Prostate cancer is the second most common cancer and the second leading cause of cancer-related deaths among men in the U.S...

3 Jun 2015

WHO accepts Elafibranor as generic name for GENFIT’s GFT505 drug candidate

GENFIT, a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that the World Health Organization (WHO) has accepted the international non-proprietary name (INN, or generic name) Elafibranor for its leading drug candidate previously referred to as GFT505.

3 Jun 2015

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

Hospira, Inc., a global leader in biosimilars, today announced that its partner, Celltrion – a global biopharmaceutical company – has received approval from ANVISA – the National Health Surveillance Agency in Brazil – for Remsima (infliximab), the first biosimilar monoclonal antibody approved for use in Brazil.

2 Jun 2015

Lucideon releases new healthcare video

Lucideon, the international materials technology company, has released a new video to showcase its services for the healthcare industries, including the medical devices, consumer healthcare and pharmaceutical sectors...

From Lucideon 2 Jun 2015

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological approach, presented clinical research from its trials using its cancer drug BPM 31510 on Phase Ib solid tumors and preclinical data on triple negative breast cancer, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2 in Chicago.

2 Jun 2015

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

2 Jun 2015

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma.

2 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) who are current smokers.

2 Jun 2015

Stable IV formulation to treat systemic susceptible and resistant Gram-positive hospital-acquired infections

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance - announces that it has developed a stable intravenous (IV) formulation of MGB-BP-3, designed for the treatment of systemic susceptible and resistant Gram-positive hospital-acquired infections.

2 Jun 2015

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

Fennec Pharmaceuticals, Inc., announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)."

2 Jun 2015

Pharmaceuticals News and Research

Researchers developing probe wire to better understand causes of degenerative brain diseases

AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

KNAUER ‘s Portfolio of LC instruments and columns as well as other high pressure equipment

Hi-Tech Pharmaceuticals signs definitive agreement to acquire FormuTech Nutrition

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

Genentech, Seragon, Regeneron and Avalanche receive Allicense 2015 Breakthrough Award for Deals of the Year

Survey shows most men with advanced prostate cancer ignore their symptoms as disease progresses

WHO accepts Elafibranor as generic name for GENFIT’s GFT505 drug candidate

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

Lucideon releases new healthcare video

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Stable IV formulation to treat systemic susceptible and resistant Gram-positive hospital-acquired infections

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring